Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

WSJ: An Easy Money Saver: the Flu Shot

flu-vaccines

The Wall Street Journal’s Avery Johnson wrote this week about a potential money saving (and health-protecting) step that’s easy to take this holiday season: getting a flu shot. Flu can result in hospitalization, especially in young or old patients and those with underlying medical issues, says Dr. Jhung. The CDC estimates that the flu costs the U.S. more than $87 billion a year and results in 17 million lost workdays. A typical flu-related hospitalization for Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Jim Greenwood Op-Ed: Time to Fund Medical Countermeasures against Threats like Ebola

Jim Greenwood

On Friday, The Hill published an op-ed from BIO President and CEO Jim Greenwood calling on Congressional appropriators to fully fund federal biodefense programs, which partner with industry to develop medical countermeasures against Ebola as well as other threats like smallpox, anthrax, and botulism toxin. President Obama’s supplemental Ebola funding request last week asked Congress to appropriate $157 million in funding for BARDA and $238 million for the National Institutes of Health to support Ebola Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

Nature Biotechnology: Outpaced by an outbreak

admin-ajax

The current issue of Nature Biotechnology contains an editorial on the response to the Ebola outbreak that is well-worth the read. The editors discuss some of the barriers which have slowed the development of Ebola medicines, including budgetary issues with federal programs designed to incentivize the development of medical countermeasures for threats like Ebola: We have no medicines to combat Ebola partly because of the time it takes to develop products—BARDA has been in existence Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Charcot-Marie-Tooth Association: Success Factors Driving Industry-Patient Group Partnerships

patient-summit-4

At this year’s BIO Patient & Health Advocacy Summit, a major theme was the power of partnerships between patient advocacy groups and other stakeholders including industry, government, and academia. One patient group which has been very successful at creating and leveraging partnerships to advance the drug development process is the Charcot-Marie-Tooth Association (CMTA), a group representing patients with Charcot-Marie-Tooth (CMT) disease. CMT is the most common hereditary motor and sensory neuropathy, affecting about 150,000 patients Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

U-T San Diego Commentary: Lack of Preparedness to Ebola Is Symptom of Larger Disease

admin-ajax

Last week, the U-T San Diego published an op-ed by Betrand Liang, CEO of Pfenex Inc., a BIO member, arguing that our current lack of vaccines and therapies for Ebola is a symptom of a larger problem. That problem, Liang argues, is a lack of funding for critical biodefense programs which Congress passed in 2004 as a way to prepare us for biological agents like anthrax, smallpox, and Ebola, as well as chemical, radiological, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,